Study how interferon works in blood cancer patients
Part of Blood & lymphatic clinical trials.
This study looks at how a medicine called pegylated interferon affects “myeloproliferative neoplasms” (MPNs), a group of slow-growing blood cancers. You may be included whether your MPN is newly diagnosed or already being treated, mainly to help researchers understand the treatment’s effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have a confirmed diagnosis of MPN (PV, TE, or MF), with your doctor planning pegylated IFN treatment
- Be covered by the French social security system (or benefit from it)
- Be able to provide extra blood samples (about 20–40 mL, or larger amounts for some PV patients)
- If your MPN has changed into acute leukemia during treatment, you may also be eligible
- Sign a study consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a type of white blood cell (monocyte) affects myeloproliferative neoplasms, a group of blood cancers. It aims to help doctors better understand these diseases and improve treatment.
This study looks at immune cells (monocytes) in people with certain blood cancers. Researchers want to understand how these cells behave and change over time. You can join if you are newly diagnosed and haven't started treatment yet.
This study looks for factors that may predict how well people with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis respond to first treatments such as hydroxyurea or pegylated interferon. It may help doctors choose better treatments by learning what differences affect outcomes.
This Phase 1 study tests PegINFa (after a bone marrow transplant) to see if it is safe and can help control myelofibrosis. You must be eligible for transplant and meet specific donor, timing, and health criteria before starting the study drug.
This trial tests a new drug called INCA036978 for people with a group of blood cancers called myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia. It aims to see if the drug is safe and works well.
This trial tests a study drug called ropeginterferon alfa-2b for people with certain blood cancers like CMML and MDS/MPN overlap syndromes. The goal is to see if it can help control the disease with fewer side effects.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.